Arteriotomy Closure Devices Market Report 2025

This Arteriotomy Closure Devices market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The arteriotomy closure devices market size has grown strongly in recent years. It will grow from $1.61 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed in the past can be attributed to several factors, including the rising number of minimally invasive surgeries, the increasing prevalence of cardiovascular diseases, greater adoption of catheterization procedures, an aging population, and a growing demand for faster recovery times.

The arteriotomy closure devices market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The anticipated growth during the forecast period can be attributed to factors such as the increasing incidence of atherosclerosis, the rising prevalence of coronary artery diseases, a heightened focus on patient safety and comfort, expanding healthcare infrastructure in developing economies, and a growing demand for ambulatory surgical centers. Key trends for this period include the use of minimally invasive techniques, the adoption of bioresorbable materials, the incorporation of automation in closure procedures, improvements in procedural efficiency, and advancements in closure devices for larger arterial punctures.

The rising prevalence of cardiovascular diseases (CVDs) is expected to drive the growth of the arteriotomy closure devices market in the coming years. CVDs encompass a range of disorders that impact the heart and blood vessels. The growing incidence of CVDs is primarily due to increasing risk factors such as poor diets, lack of physical activity, obesity, and an aging population. Arteriotomy closure devices play a critical role in cardiovascular procedures by efficiently sealing arterial puncture sites, reducing the risk of complications, and enhancing recovery after treatments such as angioplasties and catheterizations. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research organization, reported that around 7.6 million people in the UK are affected by heart and circulatory diseases, including 4 million men and 3.6 million women. This number is expected to rise by an additional 1 million by 2030 and may increase by up to 2 million by 2040. As a result, the growing prevalence of cardiovascular diseases is driving the expansion of the arteriotomy closure devices market.

Leading companies in the arteriotomy closure devices market are focusing on innovation to improve procedural efficiency, enhance patient outcomes, and address the growing demand for minimally invasive vascular access solutions. A mid-bore venous closure device is a medical instrument designed to close venous access sites created by medium-sized catheters or sheaths, helping with hemostasis and supporting patient recovery after interventional procedures. For example, in June 2024, Haemonetics Corp, a US-based healthcare firm, expanded its VASCADE product line by introducing the VASCADE MVP XL mid-bore venous closure device. This device is designed for larger sheaths (10-12F, up to 15F outer diameter) commonly used in procedures such as cryoablation. It features 58% more collagen and a bigger collapsible disc to facilitate rapid hemostasis. This addition to Haemonetics' portfolio of small- and mid-bore vascular closure solutions highlights the company’s leadership in advanced closure technology.

In February 2022, Boston Scientific Corporation, a US-based company specializing in medical technology, acquired Baylis Medical Company Inc. for $1.75 billion. This acquisition is intended to strengthen Boston Scientific's product offerings in electrophysiology and structural heart. It also incorporates Baylis Medical's cutting-edge transseptal access solutions. Baylis Medical Company Inc., based in Canada, is a medical device company known for its innovative solutions in cardiovascular procedures.

Major players in the arteriotomy closure devices market are Cardinal Health Inc., Johnson & Johnson, Abbott Laboratories, Medtronic PLC, Terumo Corporation, Teleflex Incorporated, Cook Medical Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Meril Life Sciences Pvt. Ltd., Haemonetics Corporation, Cordis Corporation, Asahi Intecc Co. Ltd., LeMaitre Vascular Inc., Cardiva Medical Inc., AccessClosure Inc., Vasorum Limited, Invamed (Pty) Ltd., Artio Medical Inc., SUTUREGARD Medical Inc., and Vivasure Medical.

North America was the largest region in the arteriotomy closure devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in arteriotomy closure devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the arteriotomy closure devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An arteriotomy closure device (ACD) is a specialized medical tool intended to seal the puncture site in an artery after procedures such as catheterization or angiography. It helps achieve hemostasis by closing the artery, minimizing the risk of bleeding, and promoting a quicker recovery compared to manual compression. ACDs are frequently employed in minimally invasive vascular procedures to improve both patient safety and the efficiency of the procedure.

Arteriotomy closure devices primarily come in two types, active closure devices and passive closure devices. Active closure devices are used to close arterial puncture sites following medical procedures, employing mechanical or mechanical-hemostatic techniques to stop bleeding and support faster recovery. These devices are used in various procedures, including those involving femoral and radial arterial access, and are employed by a variety of healthcare settings, such as hospitals, outpatient care centers, and other medical facilities.

The arteriotomy closure devices market research report is one of a series of new reports that provides arteriotomy closure devices market statistics, including the arteriotomy closure devices industry global market size, regional shares, competitors with the arteriotomy closure devices market share, detailed arteriotomy closure devices market segments, market trends, and opportunities, and any further data you may need to thrive in the arteriotomy closure devices industry. This arteriotomy closure devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The arteriotomy closure devices market consists of sales of angiograms, catheterizations, and other interventional surgeries. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.